Lauren's practice focuses on advising pharmacies, PBMs, managed care organizations and other payors on a variety of transactional, regulatory, and fraud and abuse matters.
Drawing from her experience working for the Federal Coordinated Health Care Office (the “Duals Office”) within the Centers for Medicare & Medicaid Services (CMS), she is able to provide practical advice to clients on regulatory and compliance issues relating to Medicare Advantage, Medicare Part D and Medicaid. She has advised clients on Medicare Advantage and Medicare Part D applications, audit appeals, contract negotiations, and payment issues.
Lauren also focuses much of her practice on counseling clients on various matters relating to federal and state regulatory issues, including compliance with the anti-kickback statute, corporate practice of medicine and fee-splitting prohibitions, telemedicine, and prescribing and licensing requirements. She has advised entities on compliance with the 340B Drug Pricing Program requirements. She also assists in representing clients in connection with mergers and acquisitions, provider contracts, network development programs, and general contracting.
Prior to her tenure with CMS, she was a research consultant with a health care consulting company in the DC area, working primarily with state Medicaid agencies and Medicaid managed care plans. During law school, Lauren was a member of the George Washington Journal of Energy & Environmental Law and competed in the Van Vleck Moot Court Competition.
- George Washington University (JD, with honors)
- Georgetown University (BS, cum laude)
News & Press
Biden Administration Takes Aim at Rising Drug Prices through its Executive Order on Promoting Competition
July 20, 2021 | Blog | By Theresa Carnegie, Lauren Moldawer
July 7, 2021 | Blog | By Lauren Moldawer
The provisions of the IFR apply to group health plans, health insurance issuers offering group or individual health insurance coverage, and carriers in the FEHB Program (collectively, health plans), as well as certain health care facilities. The majority of the requirements in the IRF will be effective January 1, 2022. Below, we outline the major provisions of the IFR.
Bioethics in a Pandemic: Laying the Foundation for the Draft Framework for Equitable Allocation of a COVID-19 Vaccine
September 3, 2020 | Blog | By Bridgette Keller, Lauren Moldawer
CMS Proposes Significant Changes to Medicare Advantage & Part D for 2021 and Beyond, Part 2: CMS Proposes to Codify Supplemental Benefit Rules and Update MLR
February 25, 2020 | Blog | By Tara E. Dwyer, Lauren Moldawer
CMS Proposes Significant Changes to Medicare Advantage & Part D for 2021 and Beyond, Part 1: Updates to the Star Rating System and Suspension of the Past Performance Methodology
February 13, 2020 | Blog | By Tara E. Dwyer, Lauren Moldawer
January 29, 2020 | Blog | By Lauren Moldawer
August 1, 2019 | Blog | By Lauren Moldawer
May 28, 2019 | Blog | By Bridgette Keller, Daryl Berke, Lauren Moldawer
March 22, 2019 | Blog | By Lauren Moldawer, Sarah Beth Kuyers
Framing his remarks around two key initiatives of the Administration, regulatory reform and affordable healthcare, Secretary Azar promised a bold and swift approach to regulatory reform over the coming years.
Secretary Azar discussed HHS’ initiative known as the “Regulatory Sprint to Coordinated Care,” which we’ve previously discussed on the blog. The agency is undergoing a “comprehensive reexamination of rules that may be impeding coordinated care.” As a “sprint,” he noted the goal is to issue rulemaking to alleviate impediments “as soon as possible.”